

**Genefic Specialty Pharmacy** 2577 Mall Road, Suite B Florence, AL, 35630

> Phone: (833) 928-7660 Fax: (833) 928-7661 Website: GeneficRx.com

\*Pharmacy may be listed under Watson Specialty Solutions

Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Genefic Specialty Pharmacy.

Dermatology Oral/Topical Enrollment Form			Prescriber:			NPI:		
			Supervising Physician:			NPI:		
			Address:			Tax ID:		
			Phone: Fax:					
			Contact:					
PATIENT INFORMATION           Name:         DM         D Trans M         D Trans G         DOB:         SS#:								
Image: Name         Image: Marriel Mar								
Phone:						Wt.: Ht.:		
Phone: Alt. Phone:			English Spanish Other:			w н		
PRESCRIPTION Has the patient received a loading dose/starter kit?  Yes Start Date:/ DNo SHIP TO: DPatient's Home Doctor's Office Other:								
Drug		Directions & Quantity Refills						
Olumiant®	□ 2 mg Tablet	☐ Take 2 mg PO once da	Fake 2 mg PO once daily (Quantity: 30)					
	☐ 4 mg Tablet	☐ Take 4 mg PO once da	Take 4 mg PO once daily (Quantity: 30)					
Otezla®	28 Day Starter Pack	Take as directed per pa	ake as directed per package instructions (Quantity: 55)					
	☐ 30 mg Tablet	Take 30 mg PO twice d	Fake 30 mg PO twice daily (Quantity: 60)					
Sotyktu™	6 mg Tablet	☐ Take 6 mg PO once dai	ly (Quantity: 30)					
Opzelura™	1.5 % Cream 60 gm	Apply a thin layer to affe	ected area(s) twice a day (Quantity:1 tube)					
Vtama®	1% Cream 60 gm	Apply a thin layer to affe	acted area(s) once a day (Quantity:1 tube)					
Rinvoq®	☐ 15 mg Tablet	Take 15 mg PO once d	ake 15 mg PO once daily (Quantity: 30)					
	☐ 30 mg Tablet	Take 30 mg PO once d	Take 30 mg PO once daily (Quantity: 30)					
	☐ 45 mg Tablet	Take 45 mg PO once d	Fake 45 mg PO once daily (Quantity: 30)					
MEDICAL INFORMATION								
PREVIOUS THER	ASE FAX COPY OF PRESCR APIES: Tried & Failed			AS WELL AS ANY C Contraindication:	LINICAL NOTES RE	EGARDING THERAPY***		
Hethotrexate	□ (	) [	J					
□ Soriatane	□ (	) [	J					
Clobetasol	□ (	) [	J _					
□ <sub>Stelara</sub>	□ ()		J					
□ <sub>Humira</sub>			]					
Enbrel		) [				Affected Areas		
		) [			□ <sub>Face</sub>	□ <sub>Feet</sub> □ <sub>Groin</sub>	Hands	
PHOTOTHERAPY	DTOTHERAPY Tried & Failed (Durat		uration): Not Tolerated: Contraindication:					
	□(	) [	J		BSA%	PASI Score: SALT	Score:	
□ Patient cannot afford □ Photosensitivity □ Risk of Sk		Cancer 🛛 Dista	ance from Office	Date of Diagn	osis://			
L40.0 Psoriasis	Vulgaris (Plaque Psoriasis)		ia areata, unspecified Allergies:					
L80 Vitiligo     Other:								
Active TB ruled out: □Yes □No Date:// Hep B ruled out/treated: □Yes □No Date://								
Additional Clinical Information:								
American Academy of Dermatology Consensus Statement on Psoriasis Therapies								
Psoriasis is covering greater than 10% of body surface area Psoriasis is on palms, soles, head and neck, or genitalia Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships								
PRESCRIBER SIGNATURE  To Prescriber By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations								
assistance foundations.  Prescriber: Date:								
CONFIDENTIALITY NOTICE								
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.								